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Purpose: Emerging data suggest that higher radiation doses in post-mastectomy radiotherapy may be
associated with an increased risk of reconstruction complications. This study aimed to validate previous
findings regarding the impact of radiation dose on complications among womenwith breast cancer using
a multi-center dataset.
Methods: Fifteen institutions participated, and women with breast cancer who received radiotherapy
after either autologous or prosthetic breast reconstruction were included. The primary endpoint was
major post-radiation therapy complications requiring re-operation for explantation, flap failure, or
bleeding control.
Results: In total, 314 patients were included. Radiotherapy was performed using both conventional
fractionation and hypofractionation in various schedules. The range of the radiation therapy dose invalent dose in 2 Gy fractions; HER2, human epidermal growth factor receptor 2; MROC, Mastectomy Reconstruction
astectomy radiotherapy; RT, Radiotherapy.
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n Oncology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, Republic of Korea.
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Radiation therapyEquivalent Dose in 2 Gy fractions (EQD2; a/b ¼ 3.5) varied from 43.4 to 71.0 Gy (median dose: 48.6 Gy).
Boost radiation therapy was administered to 49 patients. Major post-radiation therapy complications
were observed in 24 (7.6%) patients. In multivariate analysis, an increasing EQD2 per Gy (odds ratio [OR]:
1.58, 95% confidence interval [CI]: 1.26e1.98; p < 0.001), current smoking status (OR: 25.48, 95% CI: 1.56
e415.65; p ¼ 0.023), and prosthetic breast reconstruction (OR: 9.28, 95% CI: 1.84e46.70; p ¼ 0.007) were
independently associated with an increased risk of major complications.
Conclusion: A dose-response relationship between radiation dose and the risk of complications was
validated in this multi-center dataset. In this context, we hypothesize that the use of hypofractionated
radiotherapy (40 Gy in 15 fractions) may improve breast reconstruction outcomes. Our multi-center
prospective observational study (NCT03523078) is underway to further validate this hypothesis.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The goal of breast reconstruction for women with breast cancer
is to restore the breast mound and to improve the psychological
consequences of mastectomy. The popularity of breast recon-
struction has risenworldwide [1]. In patients with adverse features,
such as node-positive breast cancer, post-mastectomy radiotherapy
(PMRT) with regional node irradiation not only improves local
control but also survival, as shown in numerous studies [2e5].
However, PMRT with regional node irradiation can be associated
with increased toxicity such as the occurrence of fat necrosis in
patients with autologous reconstruction and high mean internal
mammary node dose [6]. Although PMRT often leads to poor
cosmesis and satisfaction outcomes in women who undergo breast
reconstruction [7], these issues have gradually been resolved with
recent advances in reconstructive and radiotherapy (RT) techniques
[8,9]. Therefore, a collaborative effort among surgeons and radia-
tion oncologists is important to mitigate complications without
increasing recurrence in the treatment of patients planning to
undergo both breast reconstruction and PMRT. For example, the
multidisciplinary ESTRO ACROP consensus guideline for target
volume definitions for chest wall irradiation after mastectomy with
immediate breast reconstruction was recently published [10].
Although efforts have been made in the field of surgery (e.g.,
microsurgical techniques and using an acellular dermal matrix) to
reduce complications and improve patient satisfaction, the PMRT
schedule has not changed much in the past decade (50 Gy using
conventional fractionation) [11]. However, advances in RT tech-
nology supporting precise conformal RT and a greater under-
standing of breast cancer biology have diversified radiation
treatments, from beam delivery to fractionation schedules. Previ-
ous studies [12,13] have shown that the practice patterns for PMRT
differ significantly between physicians. Although one would hy-
pothesize that different RT techniques varying in factors such as
fractionation, RT modality, the use of bolus, boost RT, and internal
mammary nodal RT may influence cosmetic complications, evi-
dence concerning the impact of each of these factors is lacking.
In the setting of breast-conserving surgery, hypofractionated
breast irradiation showed similar or even better cosmetic outcomes
such as moderate or marked breast shrinkage, telangiectasia, dys-
pigmentation, and breast edema compared to conventional frac-
tionation RT [14,15]. As for patients with mastectomy and breast
reconstruction, Chang et al. [16] previously reported that the level
of the radiation dose around the reconstructed breast is linked to
the risk of reconstruction complications. The study suggested that a
modification of RT treatment (e.g., by using a hypofractionated
regimen or boost RT) could determine themaximum dose level and
consequentially affect the complication rate. Considering that these
analyses were conducted only in women who underwent two-
stage prosthetic breast reconstruction at a single institution, we8
designed the present retrospective study to validate the previous
findings and to analyze the radiation dose-response relationship
for reconstruction complications after RT in a multi-institutional
cohort.
2. Materials and methods
2.1. Eligibility
A retrospectivemulti-center observational study of womenwith
breast cancer who underwent RT and breast reconstruction at 15
institutions between 2015 and 2016 was conducted after approval
from the review board of the Korean Radiation Oncology Group
(KROG 18e04). Patients treated during 2015e2016 were included;
breast reconstruction was actively performed during this period
after reimbursement from the Korean National Insurance Service,
which started in 2012. Another intention of including patients
treated during 2015e2016 and not including more recently treated
patients was to sufficiently observe reconstruction complications,
since the overall treatment period may be 1e2 years in patients
treatedwithmastectomy, adjuvant chemotherapy, adjuvant RT, and
two-stage breast reconstruction. The eligibility criteria were his-
tologically proven breast cancer, non-metastatic disease, female
sex, breast reconstruction following mastectomy, and subsequent
adjuvant RT. The exclusion criteria were bilateral breast cancer or
loss to follow-up. After approval from each participating center,
each center retrospectively reviewed the patients’ medical charts
and collected data. Treatment patterns were also collected, which
varied widely among the institutions; the patterns of practice were
analyzed separately in another report [17].
2.2. Endpoint and variables
The development of any breast reconstruction complications
and major breast reconstruction complications was collected by
medical chart review. Right or left side, which received curative
surgery and RT, were included for analysis. All complication events
that occurred during follow-upwere included in this study and pre-
RT breast complications and post-RT breast complications were
seen separately. The primary endpoint was major reconstruction
complications occurring after the completion of RT. Complication
scalewhichwas used by the prospectivemulti-center observational
Mastectomy Reconstruction Outcomes Consortium (MROC) study
was used [18]. Specific complications included seroma, hematoma,
wound dehiscence, necrosis, bleeding, contracture, infection,
cellulitis, rupture, exposure, rippling, malposition, and hernia.
Complication datawere collected by each site coordinator andwere
reviewed centrally. Major complications were defined as those
requiring re-operation for explantation, flap failure, or bleeding
control.
Table 1
Baseline patient characteristics (N ¼ 314).
N %
Age, years Median (range) 44 23e69
40 116 36.9%
>40 198 63.1%
BMI, kg/m2 Median (range) 22.6 15.7e35.6
DM Yes 14 4.5%
No 300 95.5%
Smoking No 303 96.5%
Yes, current smoker 4 1.3%
Unknown 7 2.2%
Residential area Metropolitan 219 69.7%
Non-metropolitan 95 30.3%




Clinical N stage N0 52 16.6%
Nþ 260 82.8%
Unknown 2 0.6%
Multicentricity Yes 126 40.1%
Unknown 1 0.3%
Systemic Tx 305 97.1%
Neoadjuvant chemo 149 47.5%
Adjuvant chemo 187 59.6%
Chemo regimen T-based 226 72.0%
A-based 14 4.5%
Others 65 20.7%
Endocrine Tx 230 73.2%
Anti-HER2 Tx 125 39.8%
Mastectomy Standard total 163 51.9%
Skin sparing 74 23.6%
Nipple sparing 77 24.5%




Abbreviations: A, anthracycline; BMI, body mass index; chemo, chemotherapy; DM,
diabetes mellitus; HER2, human epidermal growth factor receptor 2; T, taxane; Tx,
treatment.
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ing history, diabetes mellitus, and residential area (metropolitan vs.
non-metropolitan and rural areas). Tumor- and surgery-related
variables included clinical T and N stages, multicentricity, type of
systemic therapy (none, chemotherapy, hormonal therapy, and
anti-human epidermal growth factor receptor 2 [HER2] therapy),
type of mastectomy (standard, skin sparing, or nipple sparing), and
resection margin (clear, close, or positive). Reconstruction-related
variables included breast reconstruction sequence (one-vs. two-
stage), reconstruction timing (immediate vs. delayed), type of
breast reconstruction (autologous vs. prosthetic), type of breast
reconstruction at the time of RT (tissue expander, implant, trans-
verse rectus abdominis musculocutaneous flap, deep inferior
epigastric perforator flap, latissimus dorsi flap, or other), bilateral
breast reconstruction, and operation time. Lastly, RT-related vari-
ables included RT technique (3D conformal RT, field-in-field, step-
and-shot intensity-modulated RT, and volumetric arc therapy), ra-
diation dose/fraction, estimated maximum dose to the chest wall
on the RT planning system, chest wall boost RT, the use of bolus
material, and the use of regional RT.
2.3. Statistical analyses
Since radiation dose schedules varied widely among the in-
stitutions, the radiation dose was calculated as an Equivalent Dose
in 2 Gy fractions (EQD2) with an a/b ratio of 3.5 for equal com-
parisons of dose effects. The a/b ratio of 3.5 was estimated from
START-A trial with breast shrinkage as the endpoint [15,19]. For
analysis of postoperative breast complication rates after radio-
therapy in Table 3, patients were divided into two groups by the
median EQD2 dose 48.6 Gy. Complication rates among the groups
were analyzed using chi-square or Fisher’s exact tests. Univariate
andmultivariate analyses were performed using logistic regression,
and a backward elimination method was used for the multivariate
model. As for univariate and multivariate analyses, EQD2 dose (Gy)
was included as a continuous variable. A dose-response relation-
ship curve for major reconstruction complications was constructed
from the logistic regression analysis. All analyses were performed
using SPSS version 23.0 (IBM Inc., Armonk, NY, USA) and R version
3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).
3. Results
In total, 314 patients were included in the analysis. The baseline
characteristics of the patients are summarized in Table 1. The me-
dian age was 44 years (range, 23e69 years), and the median body
mass index was 22.6 kg/m2 (range, 15.7e35.6 kg/m2). Four (1.3%)
patients were current smokers. A total of 149 patients (47.5%)
received neoadjuvant chemotherapy, and 187 patients (59.6%)
received adjuvant chemotherapy. Two hundred thirty patients
(73.2%) received endocrine therapy, and 39.8% of the patients
received anti-HER2 therapy. Themost common type of mastectomy
was standard total mastectomy (163 patients, 51.9%). The types of
breast reconstruction and RT treatment are shown in Table 2.
Approximately half of the patients (160 patients, 51.0%) underwent
one-stage breast reconstruction. All but two patients underwent
immediate breast reconstruction; 60.5% underwent prosthetic
breast reconstruction, whereas 38.9% underwent autologous breast
reconstruction. All patients were diagnosed with unilateral breast
cancer in this study and ten percent of patients underwent bilateral
breast reconstruction. Various RT techniques were used; forward
intensity-modulated RT (field-in-field) was the most common
(40.4%), followed by volumetric arc therapy (28.7%). Conventional
fractionation was used in two-thirds of patients. In the remaining
third, hypofractionation was used with different treatment9
schedules. The most commonly used hypofraction regimen was
40.05 Gy in 15 fractions. The median radiation dose to the recon-
structed breast in terms of EQD2 (a/b ratio: 3.5) was 48.6 (range,
43.4e71.0) Gy. Boost RT was administered to 15.6% of patients
(median radiation dose: 9 [range, 3.6e21.0] Gy). Bolus was used in
53.5% of patients, depending on institutional preferences. The
majority of patients (94.3%) received RT to the regional lymph
nodes.
The postoperative breast complication rates are described in
Table 3. Major postoperative complications occurred in 30 (9.6%)
patients. Major pre- and post-RT complications occurred in 8 (2.5%)
and 24 (7.6%) patients, respectively. Median time-to-event for
major post-RT breast complicationwas 7.0 months (range, 0.1e27.0
months). At 6 months and 12 months post-RT, 9 patients and 18
patients experienced major post-RT breast complications, respec-
tively. Postoperative breast complication rates were also described
according to neoadjuvant chemotherapy and EQD2 dose groups.
Patients who received a RT dose higher than EQD2 48.6 Gy had
higher post-RT major complication rates than those who received
lower RT doses (9.5% vs. 1.4%).
The results of the univariate and multivariate analysis of major
post-RT complications are summarized in Table 4. After adjusting
for other factors, increasing EQD2 dose per Gy (odds ratio [OR]:
1.58, 95% confidence interval [CI]: 1.26e1.98; p < 0.001), current
smoking status (OR: 25.48, 95% CI: 1.56e415.65; p ¼ 0.023), and
prosthetic breast reconstruction (OR: 9.28, 95% CI: 1.84e46.70;
p ¼ 0.007) were independently associated with an increased risk of
major complications. The dose-response relationship curve, shown
Table 2










ADM use 165 52.5%
Autologous-based 122 38.9%
Both 2 0.6%
Reconstruction status at the time of RT






Bilateral reconstruction 34 10.8%
Operation time, hour Mean (SD) 6.1 3.1
RT technique
Forward IMRT (Field-in-field) 124 40.4%
VMAT 90 28.7%
3D conformal 58 18.9%
Step-and-shoot IMRT 26 8.3%
Helical tomotherapy 8 2.5%
2D (tangential) 1 0.3%
Unknown 7 2.2%
Fractionation
1.8- or 2.0-Gy fractionation 209 66.6%
45 Gy and <50 Gy 8 2.5%
50 or 50.4 Gy 192 61.1%
>50 Gy 9 2.9%
Hypofractionation 105 33.4%
40.05 Gy in 15 fractions 55 17.5%
42.56 Gy in 16 fractions 11 3.5%
45.9 Gy in 17 fractions 19 6.1%
48 Gy in 20 fractions 14 4.5%
Others 3 1.0%
RT dose in EQD2, Gy (alpha/beta ratio,
3.5)
Median (range) 48.6 (43.4e71.0)
Use of boost RT 49 15.6%
Maximum doses within the PTV, % Mean (SD) 107.6% 5.8%
Use of bolus 168 53.5%
Use of regional RT 296 94.3%
Inclusion of IMN 163 51.9%
Abbreviations: ADM, acellular dermal matrix; DIEP, deep inferior epigastric perfo-
rators flap; EQD2, equivalent dose in 2 Gy fractions; IMN, internal mammary node;
IMRT, intensity-modulated radiation therapy; LD, latissimus dorsi muscle flap; PTV,
planning target volume; RT, radiation therapy; SD, standard deviation; TRAM,
transverse rectus abdominis myocutaneous flap; VMAT, volumetric arc therapy.
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complication as the EQD2 dose increases.Table 3
Postoperative breast complication rates after neoadjuvant chemotherapy and radiothera
Total
Any Major**
Total 106 (33.8) 30 (9.6)
Group
Neoadjuvant chemotherapy
No 54 (32.7) 14 (8.5)
Yes 52 (34.9) 16 (10.7)
EQD2, Gy (alpha/beta ratio, 3.5)
< Median 27 (37.0) 1 (1.4)*
 Median 79 (32.8) 29 (12.0)*
*p < 0.05.
**Major complications were defined as those requiring re-operation for explantation, fla
Abbreviations: EQD2, equivalent dose in 2 Gy fractions; RT, radiotherapy.
10As additional analysis, multivariate analyses of major post-RT
complications were performed for each prosthetic-based and
autologous-based groups. Radiotherapy dose in EQD2 was a sig-
nificant factor for the prosthetic-based reconstruction group (OR:
1.58, 95% CI: 1.27e1.95; p < 0.001). In contrast, radiation therapy
dose in EQD2 was not a significant factor for the autologous-based
group (p ¼ 0.780).4. Discussion
In accordance with the global trend toward the restoration of
both physical and emotional health by breast reconstruction, the
proportion of patients undergoing breast reconstruction who
received RT has increased markedly in Korea since 2012, when
reimbursement from the Korean National Insurance Service started
[16,20,21]. Following a previous single-center study, we conducted
a retrospective multi-center observational analysis of 314 patients
with breast cancer who underwent RT and breast reconstruction at
15 institutions between 2015 and 2016.
In this study, the rates for any complications and major com-
plications were 38.0% and 13.5%, respectively, for irradiated pa-
tients who underwent prosthetic breast reconstruction. For
irradiated patients who underwent autologous breast reconstruc-
tion, the rates for any complication and major complications were
27.0% and 3.0%, respectively. These were slightly lower but
consistent with the findings from the MROC study, a prospective
cohort study, which aimed to evaluate and compare outcomes such
as complications and postoperative pain in patients who under-
went breast reconstruction after mastectomy. The MROC study
reported any breast complication rates of 38.9% and 25.6%,
respectively, in irradiated patients with implant reconstruction and
with autologous reconstruction; in comparison, the rates were
21.8% and 28.3% in unirradiated patients. Rates of reconstruction
failure were 18.7% and 1.0%, respectively, in patients with implant
reconstruction and with autologous reconstruction, as compared to
3.7% and 2.4% in unirradiated patients [18,22,23]. This discrepancy
may be explained by the fact that a small percentage of our patients
underwent bilateral breast reconstruction (10.8%) and that a larger
portion of patients had lower BMI. In the MROC study, bilateral
breast reconstruction and high BMI were identified as risk factors
for complications [18]. Thus, the cohort of this study may be less
susceptible to breast complications compared to cohorts observed
in Western countries (45% of patients underwent bilateral breast
reconstruction and 30.7% had BMI higher than 30 kg/m2 in the
MROC study).
In patients who received PMRT in the present study, the total
radiation dose received, current smoking status, and prosthetic
breast reconstruction were identified as independent risk factors
for the development of major post-RT breast complications. Ourpy.
Before RT After RT
Any Major** Any Major**
44 (14.0) 8 (2.5) 79 (25.2) 24 (7.6)
25 (15.2) 6 (3.6) 39 (23.6) 9 (5.5)
19 (12.8) 2 (1.3) 40 (26.8) 15 (10.1)
10 (13.7) 0 (0.0) 19 (26.0) 1 (1.4)*
34 (14.1) 8 (3.3) 60 (24.9) 23 (9.5)*
p failure, or bleeding control.
Table 4
Univariate and multivariate analyses of factors associated with major post-radiotherapy complications.
UVA MVA
Variable p OR 95% CI p
Age 0.399
BMI 0.458
DM (yes vs. no) 0.999
Smoking (yes vs. no) 0.225 25.48 1.56e415.65 0.023
Neoadjuvant chemotherapy (yes vs. no) 0.130
Adjuvant chemotherapy (yes vs. no) 0.760
Reconstruction type (Prosthetic vs. Autologous) 0.006 9.28 1.84e46.70 0.007
Reconstruction timing (Immediate vs. Delayed) 0.999
Reconstruction stage (2-stage vs. 1-stage) 0.002
Bilateral reconstruction (yes vs. no) 0.962
Radiotherapy dose in EQD2, Gy 0.005 1.58 1.26e1.98 <0.001
Boost RT (yes vs. no) 0.465
Fractionation (Hypofraction vs. Conventional) 0.079
Time interval between reconstruction and RT, months 0.074 0.87 0.73e1.04 0.130
Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; EQD2, equivalent dose in 2 Gy fractions; MVA, multivariate analysis; OR, odds ratio; RT,
radiation therapy; UVA, univariate analysis.
Fig. 1. Dose-response relationship curve for major reconstruction complications.
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with complication risk is novel. This multi-center study included
patients who were treated with a wide range of hypofractionated
regimens, which facilitated the analysis of the dose-response
relationship. Muresan et al. [24] first reported that patients with
less dose inhomogeneity (maximum dose, 58.5 Gy) due to prone
positioning technique had fewer complications than those with
greater dose inhomogeneity (maximum dose, 61.7 Gy). This finding
was corroborated by Chang et al. [16], who showed that as the near
maximum radiation dose increased, the risk of complications
increased, with an OR of 1.12 per 1-Gy increase. The authors found
that the administration of 40e42.56 Gy in 15 or 16 fractions via a
hypofractionated regimen or sparing boost RT plays a major role in
reducing near maximum dose-related complications. In the current
study, boost RT was performed generally in patients with positive
or close margins upon institutional preferences. Overall 15.6% of
the patients received boost RT, which is a fairly small percentage
compared to a US survey in 2014, in which 66.5% of responders
answered that theywould prescribe boost RT [25]. Recently, Naoum
et al. [26] investigated the impact of the addition of chest wall boost
RT on breast reconstruction morbidity. The study included 750
women (381 who received chest wall boost RT and 369 who did
not) who underwent all types of breast reconstruction during
1997e2016. The authors found that chest wall boost RT was asso-
ciated with an increased risk of complications, including infection11and skin necrosis (OR: 2.2e2.6). Our results are consistent with
these findings, which provides further evidence for a dose-
response relationship.
In the United States, a phase III randomized trial (A221505) has
been initiated by the Alliance group to compare the reconstruction
complication rate of a hypofractionated regimen using 42.56 Gy in
16 fractions with those of conventional fractionated regimens. In
Korea, we have also initiated a prospective multi-center study
(NCT03523078) to assess patient-reported outcomes and recon-
struction complication rates in patients who have undergone breast
reconstruction. Radiation details, including dose fractionation
schedules, dose inhomogeneity, and chest wall boost RT, will be
collected to investigate the dose-response relationship.
Smoking is known to increase the risk of surgical complications,
and continuing to smoke during RT leads to further problems [27].
Considering that smoking cessation greatly reduces the risk of
radiation-induced heart disease, patients should be informed of the
combined risk of breast complications from smoking and RT, and
the benefits of smoking cessation should be emphasized [28]. In
this study, smoking showed to be a significant adverse factor for
major post-RT breast complications. However, a limitation for this
analysis would be that only four patients were smokers in this
study.
Furthermore, in this study, patients who underwent prosthetic
breast reconstruction had an increased risk of major post-RT breast
complications (OR: 9.49, 95% CI: 1.85e48.65). These findings are
consistent with the results of a meta-analysis of four retrospective
studies and the prospective MROC study [22,29]. In the meta-
analysis by Barry et al. [19], autologous breast reconstruction was
associated with a reduced risk of complications than prosthetic
reconstruction in patients who underwent RT (OR: 0.20, 95% CI:
0.11e0.39). In the prospective MROC study [18], RT was associated
with a significant increase in the risk of 2-year complications in
patients who underwent implant reconstruction (OR: 2.64, 95% CI:
1.77e3.94) but not in those who underwent autologous recon-
struction (OR: 1.12, 95% CI: 0.66e1.92). Similarly, radiotherapy dose
in EQD2 remained as a significant factor in the prosthetic-based
reconstruction group, but lost its significance in the autologous-
based reconstruction group in this study. However, several other
benefits of prosthetic breast reconstruction (e.g., operative time
and salvage options after reconstruction failure) could outweigh
the risk of complications in some patients with low susceptibility
(e.g., non-smoking status, non-obese status, and unilateral breast
reconstruction) [23,30].
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delineation for patients who received post mastectomy radio-
therapy after implant-based immediate reconstruction for early
stage breast cancer was published [10]. Subsequent dosimetric
studies are perfomed using the new guideline, including one study
which showed significant dose reduction for normal heart and left
anterior descending artery with the new target volume [31]. More
studies reporting the association with the new guideline and
reconstruction complications are anticipated.
There are several limitations to this study. First, since this is a
multi-center retrospective study which collected data by medical
chart review from each institution, limitations arising from data
collection and different follow-up periods may exist. Secondly, the
surgeon factor is universally considered as the most important
factor affecting the complication rate. It would have been intriguing
if our current study included unirradiated patients with breast
reconstruction to take into account the different surgical technique
by physician or intitution and intra- and inter-surgeon variability.
Another limitation of the dose-response relationship analysis was
that a large proportion (29.6%) of the maximum dose data was
missing in instances where a composite plan could not be created.
This made the investigation of the independent impact of dose
inhomogeneity on the complication rate impossible. Because of
insurance coverage issues in Korea, bilateral reconstruction was
seldom performed in our patients. Discrepancies in body mass in-
dex, smoking rates, comorbidities, breast cup size, and desired cup
size between Korean women and their American counterparts
should also be taken into consideration when interpreting our
findings. In addition, both prosthetic-based and autologous-based
reconstruction patients were included in this study. Further elab-
orate studies concerning each types of reconstruction separately
are needed.5. Conclusions
In conclusion, smoking, prosthetic breast reconstruction, and a
higher total cumulative radiation dose were independent risk fac-
tors for major complications in this study. Our findings suggest that
there is room for improvement in reducing major reconstruction
complications, even at the time of RT, through smoking cessation
and by using a hypofractionation regimen (40 Gy in 15 fractions).
Further studies arewarranted to validate these hypothetical results.
An ongoing prospective multi-center observational study
(NCT03523078) in Korea may help guide radiation oncologists and
breast reconstruction surgeons in optimizing patient outcomes in
this clinical setting.Funding
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